In celebration of National Atrial Fibrillation Awareness Month, on September 12, Mellanie True Hills and Dr. John Day will do media interviews on TV stations across the US to raise awareness of atrial fibrillation. Get details and check the TV schedule at: Watch TV interviews across the US to celebrate National Atrial Fibrillation Awareness Month
Read More
During Atrial Fibrillation Awareness Month, StopAfib.org highlights a new video that explains the hidden afib risks. Learn more at: New StopAfib.org Video Explains the Hidden Afib Risks for Atrial Fibrillation Awareness Month
Read More
What you don't know about atrial fibrillation could kill you, or a loved one! Atrial fibrillation (also called afib) is an irregular heartbeat (or heart rhythm), and is a major cause of strokes. Having afib increases your stroke risk by 500 percent. In addition, afib can lead to heart failure, dementia, and even Alzheimer's disease. …
Read More
As reported at the European Society of Cardiology in Amsterdam, among patients with 0-2 stroke risk factors, those with atrial fibrillation had a three-fold risk of stroke over those who didn’t have afib. But that difference declined as the number of risk factors increased. The risk of stroke was high in those with 3 or …
Read More
A recent New England Journal of Medicine article reported on the results of the ARISTOTLE trial comparing the effectiveness of apixaban and warfarin for atrial fibrillation stroke prevention. Apixaban was shown to be superior to warfarin in preventing afib strokes. Learn more about the results of this trial at: Apixaban Superior to Warfarin for Atrial …
Read More
The US Food and Drug Administration has approved Xarelto (rivaroxaban) to reduce stroke risk in those with non-valvular atrial fibrillation (afib unrelated to heart valve problems). Xarelto is now the second oral alternative to warfarin (Coumadin) and offers an option for those unable to take warfarin or dabigatran. Xarelto is the first once-a-day alternative to …
Read More
The US Food & Drug Administration (FDA) Advisory Committee just voted 9-2, with 1 abstaining, to recommend that the FDA approve rivaroxaban (Xarelto) for prevention of atrial fibrillation strokes. See our full story, now up at: FDA Panel Votes for Rivaroxaban: Atrial Fibrillation Patients May Soon Have Two Alternatives to Warfarin for Stroke Prevention
Read More
Just ahead of the FDA Advisory Committee hearing on rivaroxaban for stroke prevention in atrial fibrillation, we report in more depth on the ROCKET-AF trial results published recently in the New England Journal of Medicine. Rivaroxaban was shown to be as effective as warfarin (Coumadin) for stroke prevention in a high-risk afib population. To learn …
Read More
StopAfib.org founder Mellanie True Hills with daytime TV star Susan Lucci and her husband Helmut Huber announcing Facing AFib partnership StopAfib.org is proud to participate in the Facing AFib program, which features daytime TV star Susan Lucci and her husband Helmut Huber. More than a decade ago, Huber was diagnosed with afib. Lucci and Huber …
Read More
On the heels of the US FDA approving dabigatran, the long-awaited alternative to Coumadin (warfarin), comes word that Health Canada has as well. In Canada, dabigatran is known as PRADAX™. Because this is the first alternative to warfarin in Canada, it is big news for the afib community there. Learn more at: Health Canada Approves …
Read More